The Norwegian Radium Hospital Research Foundation-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:The Norwegian Radium Hospital Research Foundation - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013310
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ノルウェー
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
The Norwegian Radium Hospital Research Foundation (RF) is a healthcare research hospital that provides clinical studies. The hospital conducts research programs and clinical studies. It offers services such as research and development. RF is a cancer research and rehabilitation center providing prevention and treatment. The hospital operates as a hub for cancer treatment and cancer research. It has established Oslo Cancer Cluster that is a development of new cancer diagnostics and medicines. The hospital caters early-stage biotech companies for the development and commercialization of their products and technologies. It identifies and promotes research projects and innovations with commercial potential. RF is headquartered in Oslo, Norway.

The Norwegian Radium Hospital Research Foundation – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
The Norwegian Radium Hospital Research Foundation, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
The Norwegian Radium Hospital Research Foundation, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
The Norwegian Radium Hospital Research Foundation, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
The Norwegian Radium Hospital Research Foundation, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
The Norwegian Radium Hospital Research Foundation, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
The Norwegian Radium Hospital Research Foundation, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Targovax Raises US$1.3 Million In Venture Financing 11
Nextera Raises Funds Through Venture Financing 12
Vaccibody Raises US$1 Million In Venture Financing 13
Targovax Raises US$2.2 Million In Series A Financing 14
Ultimovacs Raises US$2.2 Million In Venture Financing 15
Equity Offering 17
Targovax Raises USD23.6 Million in Private Placement of Shares 17
Targovax Raises USD26 Million in Private Placement of Shares 19
The Norwegian Radium Hospital Research Foundation – Key Competitors 21
The Norwegian Radium Hospital Research Foundation – Key Employees 22
The Norwegian Radium Hospital Research Foundation – Locations And Subsidiaries 23
Head Office 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
The Norwegian Radium Hospital Research Foundation, Pharmaceuticals & Healthcare, Key Facts 2
The Norwegian Radium Hospital Research Foundation, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
The Norwegian Radium Hospital Research Foundation, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
The Norwegian Radium Hospital Research Foundation, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
The Norwegian Radium Hospital Research Foundation, Deals By Therapy Area, 2011 to YTD 2017 8
The Norwegian Radium Hospital Research Foundation, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Targovax Raises US$1.3 Million In Venture Financing 11
Nextera Raises Funds Through Venture Financing 12
Vaccibody Raises US$1 Million In Venture Financing 13
Targovax Raises US$2.2 Million In Series A Financing 14
Ultimovacs Raises US$2.2 Million In Venture Financing 15
Targovax Raises USD23.6 Million in Private Placement of Shares 17
Targovax Raises USD26 Million in Private Placement of Shares 19
The Norwegian Radium Hospital Research Foundation, Key Competitors 21
The Norwegian Radium Hospital Research Foundation, Key Employees 22

★海外企業調査レポート[The Norwegian Radium Hospital Research Foundation-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • EMS SA:製薬・医療:M&Aディール及び事業提携情報
    Summary EMS SA (EMS) is a pharmaceutical company, which is focused in the development of products for improvement of health and well-being of the population. It operates in prescription segments generics, branded pharmaceuticals, OTC and hospital. It has presence in the US market through Brace Pharm …
  • Great Portland Estates Plc (GPOR):企業の財務・戦略的SWOT分析
    Great Portland Estates Plc (GPOR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Kinder Morgan Inc (KMI):石油・ガス:M&Aディール及び事業提携情報
    Summary Kinder Morgan Inc (KMI) is a midstream energy infrastructure company that owns and operates through a network of pipelines and terminals. Its pipelines transport natural gas, crude oil, gasoline, condensate, refined petroleum products and other products, and its terminals transload and store …
  • Citizen Watch Co., Ltd. (7762):企業の財務・戦略的SWOT分析
    Citizen Watch Co., Ltd. (7762) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Vysarn Ltd (MHM):企業の戦略的SWOT分析
    Vysarn Ltd (MHM) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • 84 Lumber Company:企業の戦略・SWOT・財務分析
    84 Lumber Company - Strategy, SWOT and Corporate Finance Report Summary 84 Lumber Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • GW Pharmaceuticals Plc (GWPH):製薬・医療:M&Aディール及び事業提携情報
    Summary GW Pharmaceuticals Plc (GW Pharmaceuticals) is a biopharmaceutical company that discovers, develops and commercializes novel therapeutics from its proprietary cannabinoid product platform. The company’s commercialized product, Sativex is a plant-derived cannabinoid prescription drug, for the …
  • Medison Pharma Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Medison Pharma Ltd (Medison) is marketing company which supplies and markets health care solutions to health maintenance organizations (HMO’s), medical centers, and physicians in Israel and Romania. The company offers pharmaceuticals, medical devices, and diagnostic products in the areas of …
  • Heptares Therapeutics Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Heptares Therapeutics Ltd (Heptares), a subsidiary of Sosei Group Corp is a drug discovery company that develops small-molecule drugs. The company develops drugs for targeting G-protein-coupled receptors by utilizing its drug discovery technology platforms. Its technology platforms comprise …
  • Andritz AG (ANDR):企業の財務・戦略的SWOT分析
    Andritz AG (ANDR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Protalix BioTherapeutics Inc (PLX):企業の財務・戦略的SWOT分析
    Protalix BioTherapeutics Inc (PLX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Shire plc:企業のM&A・事業提携・投資動向
    Shire plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Shire plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capita …
  • Booking Holdings Inc:企業の戦略・SWOT・財務分析
    Booking Holdings Inc - Strategy, SWOT and Corporate Finance Report Summary Booking Holdings Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Canada Energy Partners Inc (CE):石油・ガス:M&Aディール及び事業提携情報
    Summary Canada Energy Partners Inc (Canada Energy) is a natural gas exploration and development company. The company concentrates on mid-stream supplying of water disposal services, development of a wellbore mining technology and energy or mineral exploring. It develops a wellbore mining technology …
  • Redx Pharma Plc (REDX):企業の財務・戦略的SWOT分析
    Summary Redx Pharma Plc (Redx Pharma), formerly Redx Pharma Ltd is a drug discovery and development company that develops early stage and small molecule therapeutics. The company’s pipeline products include inhibitors for oncology and anti-infectives for treatment of diseases that include influenza …
  • Orexo AB (ORX):企業の財務・戦略的SWOT分析
    Orexo AB (ORX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Taiwan Power Co Ltd:電力:M&Aディール及び事業提携情報
    Summary Taiwan Power Company Ltd (Taiwan Power) is an integrated state-owned electric utility that offers electricity generation, transmission and distribution services. The utility generates electricity through various fuel resources including thermal, coal, gas, cogeneration and renewable sources. …
  • Royal Bank of Canada:企業のM&A・事業提携・投資動向
    Royal Bank of Canada - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Royal Bank of Canada Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …
  • Tokmanni Group Oyj (TOKMAN):企業の財務・戦略的SWOT分析
    Tokmanni Group Oyj (TOKMAN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • ABX Advanced Biochemical Compounds GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary ABX Advanced Biochemical Compounds GmbH (ABX), a subsidiary of Otsuka Holdings Co Ltd is a provider of biochemical compounds that manufactures, develops, and distributes biochemicals for nuclear medicine. The company provides products such as PET and SPECT precursors and reference standards, …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆